Cargando…
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837009/ https://www.ncbi.nlm.nih.gov/pubmed/20122270 http://dx.doi.org/10.1186/1471-2407-10-30 |